ateapharma.com (AVIR) Company Gross Revenue

The total trading revenue of Atea Pharmaceuticals (AVIR) on GURU.Markets is available as a chart, where 0.00 reflects the metric's latest value. This price action confirms an R&D stage characterized by high capital expenditure but promising patent scalability. Revenues are based on licenses and partnership payments for the development of COVID-19 drugs. The environmental footprint remains minimal due to production outsourcing and digital documentation.

Atea Pharma (AVIR): Company Sales from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for Atea Pharma (AVIR)

- price and consensus price forecast:

Stock Price ateapharma.com|AVIR - Price Target Chart

- market capitalization details:

Market Capitalization Atea Pharma|AVIR - Enterprise Value

- book capitalization data:

Book Value per Share Atea Pharmaceuticals|AVIR - Company Net Assets|Market Cap to Book Value Multiple ateapharma.com|AVIR - Company Total Assets

- debt and solvency information:

- net income and valuation ratios data:

AVIR - Net Profit|Projected Future Earnings Atea Pharmaceuticals|AVIR - Price to Earnings Ratio|Future Price to Earnings Multiple Atea Pharma|AVIR - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Atea Pharma|AVIR - Operating profit EBITDA|Net earnings per share (EPS TTM) Atea Pharmaceuticals|AVIR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months ateapharma.com|AVIR - Earnings growth in current year|Expected net earnings per share growth next year Atea Pharmaceuticals

- issuer revenue and sales details:

AVIR - Company Sales|Projected Sales Volume Atea Pharmaceuticals, Inc.|AVIR - Market Cap to Revenue|Price to Expected Revenue Ratio Atea Pharma

General company analysis:ateapharma.com - AVIR

Original product of Atea Pharmaceuticals, Inc.

A defensive portfolio is constructed by filtering out speculative noise using fundamental metrics. This indicator tracks daily cash inflows from product sales, measuring actual customer purchasing activity. For Atea Pharmaceuticals (AVIR), this reflects the commercialization of patents for treating viral infections and the stability of revenues from chronic patients. Revenue dynamics confirm the viability of the business model. Constant monitoring of the company's sales allows for the timely recognition of a trend reversal.

Analysis of competing companies